CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: PRKCA (ImmuneEditome ID:5578)

1. Gene summary of enriched editing regions for PRKCA

check button Gene summary
Gene informationGene symbol

PRKCA

Gene ID

5578

GeneSynonymsAAG6|PKC-alpha|PKCA|PKCI+/-|PKCalpha|PRKACA
GeneCytomap

17q24.2

GeneTypeprotein-coding
GeneDescriptionprotein kinase C alpha type|PKC-A|aging-associated gene 6
GeneModificationdate20230521
UniprotIDP17252;J3KRN5;L7RSM7
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr17:66378701-66378899:+ENST00000284384.6ENSG00000154229.10PRKCAintronicAluSzchr17:66378701-66378899:+.alignment
chr17:66378701-66378899:+ENST00000413366.6ENSG00000154229.10PRKCAintronicAluSzchr17:66378701-66378899:+.alignment
chr17:66378701-66378899:+ENST00000578063.4ENSG00000154229.10PRKCAintronicAluSzchr17:66378701-66378899:+.alignment
chr17:66459123-66459303:+ENST00000284384.6ENSG00000154229.10PRKCAintronicAluJbchr17:66459123-66459303:+.alignment
chr17:66459123-66459303:+ENST00000413366.6ENSG00000154229.10PRKCAintronicAluJbchr17:66459123-66459303:+.alignment
chr17:66459123-66459303:+ENST00000578063.4ENSG00000154229.10PRKCAintronicAluJbchr17:66459123-66459303:+.alignment
chr17:66496695-66497385:+ENST00000284384.6ENSG00000154229.10PRKCAintronicAluSz,AluSpchr17:66496695-66497385:+.alignment
chr17:66496695-66497385:+ENST00000413366.6ENSG00000154229.10PRKCAintronicAluSz,AluSpchr17:66496695-66497385:+.alignment
chr17:66496695-66497385:+ENST00000578063.4ENSG00000154229.10PRKCAintronicAluSz,AluSpchr17:66496695-66497385:+.alignment
chr17:66498940-66500006:+ENST00000284384.6ENSG00000154229.10PRKCAintronicMLT1A1,MLT1A0,L2achr17:66498940-66500006:+.alignment
chr17:66498940-66500006:+ENST00000413366.6ENSG00000154229.10PRKCAintronicMLT1A1,MLT1A0,L2achr17:66498940-66500006:+.alignment
chr17:66498940-66500006:+ENST00000578063.4ENSG00000154229.10PRKCAintronicMLT1A1,MLT1A0,L2achr17:66498940-66500006:+.alignment
chr17:66543131-66543598:+ENST00000284384.6ENSG00000154229.10PRKCAintronicNoRepeatchr17:66543131-66543598:+.alignment
chr17:66543131-66543598:+ENST00000413366.6ENSG00000154229.10PRKCAintronicNoRepeatchr17:66543131-66543598:+.alignment
chr17:66543131-66543598:+ENST00000578063.4ENSG00000154229.10PRKCAintronicNoRepeatchr17:66543131-66543598:+.alignment
chr17:66552102-66552275:+ENST00000284384.6ENSG00000154229.10PRKCAintronicAluJbchr17:66552102-66552275:+.alignment
chr17:66552102-66552275:+ENST00000413366.6ENSG00000154229.10PRKCAintronicAluJbchr17:66552102-66552275:+.alignment
chr17:66552102-66552275:+ENST00000578063.4ENSG00000154229.10PRKCAintronicAluJbchr17:66552102-66552275:+.alignment
chr17:66591171-66592189:+ENST00000284384.6ENSG00000154229.10PRKCAintronicAluSx,AluJbchr17:66591171-66592189:+.alignment
chr17:66591171-66592189:+ENST00000413366.6ENSG00000154229.10PRKCAintronicAluSx,AluJbchr17:66591171-66592189:+.alignment
chr17:66591171-66592189:+ENST00000578063.4ENSG00000154229.10PRKCAintronicAluSx,AluJbchr17:66591171-66592189:+.alignment
chr17:66612153-66612310:+ENST00000284384.6ENSG00000154229.10PRKCAintronicAluSq2chr17:66612153-66612310:+.alignment
chr17:66612153-66612310:+ENST00000413366.6ENSG00000154229.10PRKCAintronicAluSq2chr17:66612153-66612310:+.alignment
chr17:66612153-66612310:+ENST00000578063.4ENSG00000154229.10PRKCAintronicAluSq2chr17:66612153-66612310:+.alignment
chr17:66698827-66699735:+ENST00000284384.6ENSG00000154229.10PRKCAintronicL1MA9,AluSz6,AluJr,FAMchr17:66698827-66699735:+.alignment
chr17:66698827-66699735:+ENST00000413366.6ENSG00000154229.10PRKCAintronicL1MA9,AluSz6,AluJr,FAMchr17:66698827-66699735:+.alignment
chr17:66698827-66699735:+ENST00000578063.4ENSG00000154229.10PRKCAintronicL1MA9,AluSz6,AluJr,FAMchr17:66698827-66699735:+.alignment
chr17:66780909-66782088:+ENST00000413366.6ENSG00000154229.10PRKCAintronic(AT)n,(GTGTGT)n,L1MB3,AluSg,AluSz,MLT1I,(AG)nchr17:66780909-66782088:+.alignment


Top

2. Tumor-specific enriched editing regions for PRKCA


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for PRKCA


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for PRKCA


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

5. Enriched editing regions and immune infiltration for PRKCA


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr17:66698827-66699735:+ESCAEERT_cells_gamma_delta3.4473e-020.2588image
ENSG00000154229.10,PRKCAESCAEAGT_cells_gamma_delta1.2098e-020.2865image
ENSG00000154229.10,PRKCALAMLEAGNeutrophils2.2058e-02-0.4235image
chr17:66591171-66592189:+STADEERT_cells_gamma_delta2.8925e-100.9392image
chr17:66698827-66699735:+STADEERMacrophages_M13.7527e-020.1689image
ENSG00000154229.10,PRKCASTADEAGT_cells_gamma_delta3.7375e-020.1562image


Top

6. Enriched editing regions and immune gene sets for PRKCA


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr17:66698827-66699735:+ESCAGSVA_HALLMARK_P53_PATHWAYEER4.8678e-030.3401image
ENSG00000154229.10,PRKCAESCAGSVA_HALLMARK_PROTEIN_SECRETIONEAG8.1176e-030.3015image
ENSG00000154229.10,PRKCASTADGSVA_HALLMARK_APOPTOSISEAG2.1633e-030.2284image
chr17:66591171-66592189:+STADGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER4.9594e-020.4336image
chr17:66698827-66699735:+STADGSVA_HALLMARK_APOPTOSISEER6.0324e-030.2218image


Top

7. Enriched editing regions and drugs for PRKCA


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr17:66698827-66699735:+ESCAMethotrexateEER3.8894e-030.3482image
ENSG00000154229.10,PRKCAESCACamptothecinEAG1.2668e-020.2847image
ENSG00000154229.10,PRKCALAMLATRAEAG7.6766e-030.4849image
ENSG00000154229.10,PRKCAOVAS601245EAG4.3451e-020.4246image
ENSG00000154229.10,PRKCASTADAZD6244EAG2.7521e-02-0.1652image
chr17:66591171-66592189:+STADBexaroteneEER5.1054e-030.5875image
chr17:66698827-66699735:+STADAG.014699EER3.0903e-030.2385image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType
chr17:66378701-66378899:+ENST00000413366.6P17252DB00163Vitamin ESmallMoleculeDrug
chr17:66378701-66378899:+ENST00000413366.6P17252DB00675TamoxifenSmallMoleculeDrug
chr17:66378701-66378899:+ENST00000413366.6P17252DB04209DequaliniumSmallMoleculeDrug
chr17:66378701-66378899:+ENST00000413366.6P17252DB05013Ingenol mebutateSmallMoleculeDrug
chr17:66378701-66378899:+ENST00000413366.6P17252DB06595MidostaurinSmallMoleculeDrug
chr17:66378701-66378899:+ENST00000413366.6P17252DB09096Benzoyl peroxideSmallMoleculeDrug
chr17:66378701-66378899:+ENST00000413366.6P17252DB14001alpha-Tocopherol succinateSmallMoleculeDrug
chr17:66378701-66378899:+ENST00000413366.6P17252DB14002D-alpha-Tocopherol acetateSmallMoleculeDrug
chr17:66459123-66459303:+ENST00000413366.6P17252DB00163Vitamin ESmallMoleculeDrug
chr17:66459123-66459303:+ENST00000413366.6P17252DB00675TamoxifenSmallMoleculeDrug
chr17:66459123-66459303:+ENST00000413366.6P17252DB04209DequaliniumSmallMoleculeDrug
chr17:66459123-66459303:+ENST00000413366.6P17252DB05013Ingenol mebutateSmallMoleculeDrug
chr17:66459123-66459303:+ENST00000413366.6P17252DB06595MidostaurinSmallMoleculeDrug
chr17:66459123-66459303:+ENST00000413366.6P17252DB09096Benzoyl peroxideSmallMoleculeDrug
chr17:66459123-66459303:+ENST00000413366.6P17252DB14001alpha-Tocopherol succinateSmallMoleculeDrug
chr17:66459123-66459303:+ENST00000413366.6P17252DB14002D-alpha-Tocopherol acetateSmallMoleculeDrug
chr17:66496695-66497385:+ENST00000413366.6P17252DB00163Vitamin ESmallMoleculeDrug
chr17:66496695-66497385:+ENST00000413366.6P17252DB00675TamoxifenSmallMoleculeDrug
chr17:66496695-66497385:+ENST00000413366.6P17252DB04209DequaliniumSmallMoleculeDrug
chr17:66496695-66497385:+ENST00000413366.6P17252DB05013Ingenol mebutateSmallMoleculeDrug
chr17:66496695-66497385:+ENST00000413366.6P17252DB06595MidostaurinSmallMoleculeDrug
chr17:66496695-66497385:+ENST00000413366.6P17252DB09096Benzoyl peroxideSmallMoleculeDrug
chr17:66496695-66497385:+ENST00000413366.6P17252DB14001alpha-Tocopherol succinateSmallMoleculeDrug
chr17:66496695-66497385:+ENST00000413366.6P17252DB14002D-alpha-Tocopherol acetateSmallMoleculeDrug
chr17:66498940-66500006:+ENST00000413366.6P17252DB00163Vitamin ESmallMoleculeDrug
chr17:66498940-66500006:+ENST00000413366.6P17252DB00675TamoxifenSmallMoleculeDrug
chr17:66498940-66500006:+ENST00000413366.6P17252DB04209DequaliniumSmallMoleculeDrug
chr17:66498940-66500006:+ENST00000413366.6P17252DB05013Ingenol mebutateSmallMoleculeDrug
chr17:66498940-66500006:+ENST00000413366.6P17252DB06595MidostaurinSmallMoleculeDrug
chr17:66498940-66500006:+ENST00000413366.6P17252DB09096Benzoyl peroxideSmallMoleculeDrug
chr17:66498940-66500006:+ENST00000413366.6P17252DB14001alpha-Tocopherol succinateSmallMoleculeDrug
chr17:66498940-66500006:+ENST00000413366.6P17252DB14002D-alpha-Tocopherol acetateSmallMoleculeDrug
chr17:66543131-66543598:+ENST00000413366.6P17252DB00163Vitamin ESmallMoleculeDrug
chr17:66543131-66543598:+ENST00000413366.6P17252DB00675TamoxifenSmallMoleculeDrug
chr17:66543131-66543598:+ENST00000413366.6P17252DB04209DequaliniumSmallMoleculeDrug
chr17:66543131-66543598:+ENST00000413366.6P17252DB05013Ingenol mebutateSmallMoleculeDrug
chr17:66543131-66543598:+ENST00000413366.6P17252DB06595MidostaurinSmallMoleculeDrug
chr17:66543131-66543598:+ENST00000413366.6P17252DB09096Benzoyl peroxideSmallMoleculeDrug
chr17:66543131-66543598:+ENST00000413366.6P17252DB14001alpha-Tocopherol succinateSmallMoleculeDrug
chr17:66543131-66543598:+ENST00000413366.6P17252DB14002D-alpha-Tocopherol acetateSmallMoleculeDrug
chr17:66552102-66552275:+ENST00000413366.6P17252DB00163Vitamin ESmallMoleculeDrug
chr17:66552102-66552275:+ENST00000413366.6P17252DB00675TamoxifenSmallMoleculeDrug
chr17:66552102-66552275:+ENST00000413366.6P17252DB04209DequaliniumSmallMoleculeDrug
chr17:66552102-66552275:+ENST00000413366.6P17252DB05013Ingenol mebutateSmallMoleculeDrug
chr17:66552102-66552275:+ENST00000413366.6P17252DB06595MidostaurinSmallMoleculeDrug
chr17:66552102-66552275:+ENST00000413366.6P17252DB09096Benzoyl peroxideSmallMoleculeDrug
chr17:66552102-66552275:+ENST00000413366.6P17252DB14001alpha-Tocopherol succinateSmallMoleculeDrug
chr17:66552102-66552275:+ENST00000413366.6P17252DB14002D-alpha-Tocopherol acetateSmallMoleculeDrug
chr17:66591171-66592189:+ENST00000413366.6P17252DB00163Vitamin ESmallMoleculeDrug
chr17:66591171-66592189:+ENST00000413366.6P17252DB00675TamoxifenSmallMoleculeDrug
chr17:66591171-66592189:+ENST00000413366.6P17252DB04209DequaliniumSmallMoleculeDrug
chr17:66591171-66592189:+ENST00000413366.6P17252DB05013Ingenol mebutateSmallMoleculeDrug
chr17:66591171-66592189:+ENST00000413366.6P17252DB06595MidostaurinSmallMoleculeDrug
chr17:66591171-66592189:+ENST00000413366.6P17252DB09096Benzoyl peroxideSmallMoleculeDrug
chr17:66591171-66592189:+ENST00000413366.6P17252DB14001alpha-Tocopherol succinateSmallMoleculeDrug
chr17:66591171-66592189:+ENST00000413366.6P17252DB14002D-alpha-Tocopherol acetateSmallMoleculeDrug
chr17:66612153-66612310:+ENST00000413366.6P17252DB00163Vitamin ESmallMoleculeDrug
chr17:66612153-66612310:+ENST00000413366.6P17252DB00675TamoxifenSmallMoleculeDrug
chr17:66612153-66612310:+ENST00000413366.6P17252DB04209DequaliniumSmallMoleculeDrug
chr17:66612153-66612310:+ENST00000413366.6P17252DB05013Ingenol mebutateSmallMoleculeDrug
chr17:66612153-66612310:+ENST00000413366.6P17252DB06595MidostaurinSmallMoleculeDrug
chr17:66612153-66612310:+ENST00000413366.6P17252DB09096Benzoyl peroxideSmallMoleculeDrug
chr17:66612153-66612310:+ENST00000413366.6P17252DB14001alpha-Tocopherol succinateSmallMoleculeDrug
chr17:66612153-66612310:+ENST00000413366.6P17252DB14002D-alpha-Tocopherol acetateSmallMoleculeDrug
chr17:66698827-66699735:+ENST00000413366.6P17252DB00163Vitamin ESmallMoleculeDrug
chr17:66698827-66699735:+ENST00000413366.6P17252DB00675TamoxifenSmallMoleculeDrug
chr17:66698827-66699735:+ENST00000413366.6P17252DB04209DequaliniumSmallMoleculeDrug
chr17:66698827-66699735:+ENST00000413366.6P17252DB05013Ingenol mebutateSmallMoleculeDrug
chr17:66698827-66699735:+ENST00000413366.6P17252DB06595MidostaurinSmallMoleculeDrug
chr17:66698827-66699735:+ENST00000413366.6P17252DB09096Benzoyl peroxideSmallMoleculeDrug
chr17:66698827-66699735:+ENST00000413366.6P17252DB14001alpha-Tocopherol succinateSmallMoleculeDrug
chr17:66698827-66699735:+ENST00000413366.6P17252DB14002D-alpha-Tocopherol acetateSmallMoleculeDrug
chr17:66780909-66782088:+ENST00000413366.6P17252DB00163Vitamin ESmallMoleculeDrug
chr17:66780909-66782088:+ENST00000413366.6P17252DB00675TamoxifenSmallMoleculeDrug
chr17:66780909-66782088:+ENST00000413366.6P17252DB04209DequaliniumSmallMoleculeDrug
chr17:66780909-66782088:+ENST00000413366.6P17252DB05013Ingenol mebutateSmallMoleculeDrug
chr17:66780909-66782088:+ENST00000413366.6P17252DB06595MidostaurinSmallMoleculeDrug
chr17:66780909-66782088:+ENST00000413366.6P17252DB09096Benzoyl peroxideSmallMoleculeDrug
chr17:66780909-66782088:+ENST00000413366.6P17252DB14001alpha-Tocopherol succinateSmallMoleculeDrug
chr17:66780909-66782088:+ENST00000413366.6P17252DB14002D-alpha-Tocopherol acetateSmallMoleculeDrug